178 related articles for article (PubMed ID: 29950528)
21. ALK-negative anaplastic large cell lymphoma, null type with aberrant expression of PAX5 and CD138: A diagnostic pitfall.
Salyana MA; Khan S; Zhang X
Diagn Cytopathol; 2021 Oct; 49(10):E395-E399. PubMed ID: 34190415
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic Utility of PAX5 in Hodgkin and Non-Hodgkin Lymphoma: A Study from Northern India.
Johri N; Patne SC; Tewari M; Kumar M
J Clin Diagn Res; 2016 Aug; 10(8):XC04-XC07. PubMed ID: 27656544
[TBL] [Abstract][Full Text] [Related]
23. Immunoprofile of Hodgkin's lymphoma in India.
Patkar N; Mehta J; Kulkarni B; Pande R; Advani S; Borges A
Indian J Cancer; 2008; 45(2):59-63. PubMed ID: 18626150
[TBL] [Abstract][Full Text] [Related]
24. ALK-negative anaplastic large cell lymphoma with "Hodgkin-like" cytomorphology and nuclear expression of PAX5.
Fratoni S; Niscola P; Zhao XF; Larocca LM; Capalbo A; Fabbretti M; Bernardini L; Abruzzese E
Pathol Res Pract; 2020 Feb; 216(2):152724. PubMed ID: 31784094
[TBL] [Abstract][Full Text] [Related]
25. Frequent expression of follicular dendritic cell markers in Hodgkin lymphoma and anaplastic large cell lymphoma.
Kim SH; Choe JY; Jeon Y; Huh J; Jung HR; Choi YD; Kim HJ; Cha HJ; Park WS; Kim JE
J Clin Pathol; 2013 Jul; 66(7):589-96. PubMed ID: 23454725
[TBL] [Abstract][Full Text] [Related]
26. The complementary role of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in diagnosis of Hodgkin's lymphoma.
Masoud R; Ibrahiem A; Tantawy D; Eldosoky I
Ann Diagn Pathol; 2019 Oct; 42():64-68. PubMed ID: 31319330
[TBL] [Abstract][Full Text] [Related]
27. [KI-1-positive, anaplastic, large-cell lymphoma related to Hodgkin's disease].
Veiga M; Fresno MF; Pérez del Río MJ; García I; Madrigal B; Herrero A
Sangre (Barc); 1997 Feb; 42(1):81-4. PubMed ID: 9229809
[TBL] [Abstract][Full Text] [Related]
28. Inflammatory malignant fibrous histiocytoma: distinction from Hodgkin's disease and non-Hodgkin's lymphoma by a panel of leukocyte markers.
Khalidi HS; Singleton TP; Weiss SW
Mod Pathol; 1997 May; 10(5):438-42. PubMed ID: 9160307
[TBL] [Abstract][Full Text] [Related]
29. Primary cutaneous CD30 positive T-cell lymphoproliferative disorders with aberrant expression of PAX5: report of three cases.
Hagiwara M; Tomita A; Takata K; Shimoyama Y; Yoshino T; Tomita Y; Nakamura S
Pathol Int; 2012 Apr; 62(4):264-70. PubMed ID: 22449230
[TBL] [Abstract][Full Text] [Related]
30. A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma.
Döring C; Hansmann ML; Agostinelli C; Piccaluga PP; Facchetti F; Pileri S; Küppers R; Newrzela S; Hartmann S
Mod Pathol; 2014 Oct; 27(10):1345-54. PubMed ID: 24633193
[TBL] [Abstract][Full Text] [Related]
31. Hodgkin's lymphoma. An immunohistochemical profile in northern Iraq.
Fadhil MS; Al-Nueimy WM; Lazim AF
Saudi Med J; 2014 May; 35(5):448-53. PubMed ID: 24825804
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
Benner MF; Jansen PM; Meijer CJ; Willemze R
Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
[TBL] [Abstract][Full Text] [Related]
33. Variable expression of B-cell transcription factors in reactive immunoblastic proliferations: a potential mimic of classical Hodgkin lymphoma.
Treetipsatit J; Rimzsa L; Grogan T; Warnke RA; Natkunam Y
Am J Surg Pathol; 2014 Dec; 38(12):1655-63. PubMed ID: 24921642
[TBL] [Abstract][Full Text] [Related]
34. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
[TBL] [Abstract][Full Text] [Related]
35. T-cell variant of classical Hodgkin's lymphoma with nodal and cutaneous manifestations demonstrated by single-cell polymerase chain reaction.
Willenbrock K; Ichinohasama R; Kadin ME; Miura I; Terui T; Meguro K; Fukuhara O; DeCoteau JF; Hansmann ML
Lab Invest; 2002 Sep; 82(9):1103-9. PubMed ID: 12218070
[TBL] [Abstract][Full Text] [Related]
36. [Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: clinicopathologic characterization of 16 cases showing different patterns].
Wang L; Wang W; Li X; Guo Y; Zhu X
Zhonghua Bing Li Xue Za Zhi; 2014 May; 43(5):307-12. PubMed ID: 25030862
[TBL] [Abstract][Full Text] [Related]
37. Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Swinburn P; Shingler S; Acaster S; Lloyd A; Bonthapally V
Leuk Lymphoma; 2015 Jun; 56(6):1839-45. PubMed ID: 25284490
[TBL] [Abstract][Full Text] [Related]
38. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.
Ramos CA; Ballard B; Zhang H; Dakhova O; Gee AP; Mei Z; Bilgi M; Wu MF; Liu H; Grilley B; Bollard CM; Chang BH; Rooney CM; Brenner MK; Heslop HE; Dotti G; Savoldo B
J Clin Invest; 2017 Sep; 127(9):3462-3471. PubMed ID: 28805662
[TBL] [Abstract][Full Text] [Related]
39. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.
de Claro RA; McGinn K; Kwitkowski V; Bullock J; Khandelwal A; Habtemariam B; Ouyang Y; Saber H; Lee K; Koti K; Rothmann M; Shapiro M; Borrego F; Clouse K; Chen XH; Brown J; Akinsanya L; Kane R; Kaminskas E; Farrell A; Pazdur R
Clin Cancer Res; 2012 Nov; 18(21):5845-9. PubMed ID: 22962441
[TBL] [Abstract][Full Text] [Related]
40. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.
Rinaldi I
Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
